Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

Ähnliche Einträge

• Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
  von: Kriegsmann, Katharina, et al.
  Veröffentlicht: (2016)
• Salvage chemotherapy with R-DHAP in patients with relapsed or refractory non-Hodgkin lymphoma
  von: Schirmbeck, Nadine, et al.
  Veröffentlicht: (2016)
• The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL: results from the Phase-II STORM Trial
  von: Witzens-Harig, Mathias, et al.
  Veröffentlicht: (2021)
• Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with diffuse large b cell lymphoma
  von: Kriegsmann, Katharina, et al.
  Veröffentlicht: (2016)
• A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial
  von: Witzens-Harig, Mathias, et al.
  Veröffentlicht: (2013)